Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04290546 · ClinicalTrials.gov registry record · Phase 1
CIML NK Cell in Head & Neck Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04290546 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 11 participants.
The verdict
NCT04290546, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer. This research study involves the following drugs and biologics: * CIML NK donor cells * IL-15 superagonist * Ipilimumab * Cetuximab
Interventions
- DRUG Ipilimumab
- DRUG Cetuximab
- DRUG Interleukin-15 Superagonist (N-803)
- BIOLOGICAL CIML NK cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2024-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04290546
The ClinicalTrials.gov registry entry for NCT04290546 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ipilimumab is the first listed.
NCT04290546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04290546 about?
NCT04290546 is a clinical study titled "CIML NK Cell in Head & Neck Cancer". This research study is evaluating the safety and efficacy of a combination drug and biologic therapy in patients with advanced head and neck cancer. This research study involves the following drugs and biologics: * CIML NK donor cells * IL-15 superagonist * Ipilimumab * Cetuximab
What is the current status of trial NCT04290546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2020-07-20. Estimated completion is 2024-12-16.
What interventions are being tested in trial NCT04290546?
The interventions under investigation include: Ipilimumab (DRUG), Cetuximab (DRUG), Interleukin-15 Superagonist (N-803) (DRUG), CIML NK cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT04290546?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.